Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease

Research output: Contribution to journalArticle

Standard

Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. / Ye, Zheng; Altena, Ellemarije; Nombela, Cristina; Housden, Charlotte R; Maxwell, Helen; Rittman, Timothy; Huddleston, Chelan; Rae, Charlotte L; Regenthal, Ralf; Sahakian, Barbara J; Barker, Roger A; Robbins, Trevor W; Rowe, James B.

In: Brain, Vol. 137, No. Pt 4, 04.2014, p. 1145-55.

Research output: Contribution to journalArticle

Harvard

Ye, Z, Altena, E, Nombela, C, Housden, CR, Maxwell, H, Rittman, T, Huddleston, C, Rae, CL, Regenthal, R, Sahakian, BJ, Barker, RA, Robbins, TW & Rowe, JB 2014, 'Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease', Brain, vol. 137, no. Pt 4, pp. 1145-55. https://doi.org/10.1093/brain/awu032

APA

Ye, Z., Altena, E., Nombela, C., Housden, C. R., Maxwell, H., Rittman, T., Huddleston, C., Rae, C. L., Regenthal, R., Sahakian, B. J., Barker, R. A., Robbins, T. W., & Rowe, J. B. (2014). Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain, 137(Pt 4), 1145-55. https://doi.org/10.1093/brain/awu032

CBE

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. 2014. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain. 137(Pt 4):1145-55. https://doi.org/10.1093/brain/awu032

MLA

Vancouver

Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T et al. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain. 2014 Apr;137(Pt 4):1145-55. https://doi.org/10.1093/brain/awu032

Author

Ye, Zheng ; Altena, Ellemarije ; Nombela, Cristina ; Housden, Charlotte R ; Maxwell, Helen ; Rittman, Timothy ; Huddleston, Chelan ; Rae, Charlotte L ; Regenthal, Ralf ; Sahakian, Barbara J ; Barker, Roger A ; Robbins, Trevor W ; Rowe, James B. / Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. In: Brain. 2014 ; Vol. 137, No. Pt 4. pp. 1145-55.

RIS

TY - JOUR

T1 - Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease

AU - Ye, Zheng

AU - Altena, Ellemarije

AU - Nombela, Cristina

AU - Housden, Charlotte R

AU - Maxwell, Helen

AU - Rittman, Timothy

AU - Huddleston, Chelan

AU - Rae, Charlotte L

AU - Regenthal, Ralf

AU - Sahakian, Barbara J

AU - Barker, Roger A

AU - Robbins, Trevor W

AU - Rowe, James B

PY - 2014/4

Y1 - 2014/4

N2 - Impulsivity is common in Parkinson's disease even in the absence of impulse control disorders. It is likely to be multifactorial, including a dopaminergic 'overdose' and structural changes in the frontostriatal circuits for motor control. In addition, we proposed that changes in serotonergic projections to the forebrain also contribute to response inhibition in Parkinson's disease, based on preclinical animal and human studies. We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves response inhibition, in terms of both behaviour and the efficiency of underlying neural mechanisms. This multimodal magnetic resonance imaging study used a double-blind randomized placebo-controlled crossover design with an integrated Stop-Signal and NoGo paradigm. Twenty-one patients with idiopathic Parkinson's disease (46-76 years old, 11 male, Hoehn and Yahr stage 1.5-3) received 30 mg citalopram or placebo in addition to their usual dopaminergic medication in two separate sessions. Twenty matched healthy control subjects (54-74 years old, 12 male) were tested without medication. The effects of disease and drug on behavioural performance and regional brain activity were analysed using general linear models. In addition, anatomical connectivity was examined using diffusion tensor imaging and tract-based spatial statistics. We confirmed that Parkinson's disease caused impairment in response inhibition, with longer Stop-Signal Reaction Time and more NoGo errors under placebo compared with controls, without affecting Go reaction times. This was associated with less stop-specific activation in the right inferior frontal cortex, but no significant difference in NoGo-related activation. Although there was no beneficial main effect of citalopram, it reduced Stop-Signal Reaction Time and NoGo errors, and enhanced inferior frontal activation, in patients with relatively more severe disease (higher Unified Parkinson's Disease Rating Scale motor score). The behavioural effect correlated with the citalopram-induced enhancement of prefrontal activation and the strength of preserved structural connectivity between the frontal and striatal regions. In conclusion, the behavioural effect of citalopram on response inhibition depends on individual differences in prefrontal cortical activation and frontostriatal connectivity. The correlation between disease severity and the effect of citalopram on response inhibition may be due to the progressive loss of forebrain serotonergic projections. These results contribute to a broader understanding of the critical roles of serotonin in regulating cognitive and behavioural control, as well as new strategies for patient stratification in clinical trials of serotonergic treatments in Parkinson's disease.

AB - Impulsivity is common in Parkinson's disease even in the absence of impulse control disorders. It is likely to be multifactorial, including a dopaminergic 'overdose' and structural changes in the frontostriatal circuits for motor control. In addition, we proposed that changes in serotonergic projections to the forebrain also contribute to response inhibition in Parkinson's disease, based on preclinical animal and human studies. We therefore examined whether the selective serotonin reuptake inhibitor citalopram improves response inhibition, in terms of both behaviour and the efficiency of underlying neural mechanisms. This multimodal magnetic resonance imaging study used a double-blind randomized placebo-controlled crossover design with an integrated Stop-Signal and NoGo paradigm. Twenty-one patients with idiopathic Parkinson's disease (46-76 years old, 11 male, Hoehn and Yahr stage 1.5-3) received 30 mg citalopram or placebo in addition to their usual dopaminergic medication in two separate sessions. Twenty matched healthy control subjects (54-74 years old, 12 male) were tested without medication. The effects of disease and drug on behavioural performance and regional brain activity were analysed using general linear models. In addition, anatomical connectivity was examined using diffusion tensor imaging and tract-based spatial statistics. We confirmed that Parkinson's disease caused impairment in response inhibition, with longer Stop-Signal Reaction Time and more NoGo errors under placebo compared with controls, without affecting Go reaction times. This was associated with less stop-specific activation in the right inferior frontal cortex, but no significant difference in NoGo-related activation. Although there was no beneficial main effect of citalopram, it reduced Stop-Signal Reaction Time and NoGo errors, and enhanced inferior frontal activation, in patients with relatively more severe disease (higher Unified Parkinson's Disease Rating Scale motor score). The behavioural effect correlated with the citalopram-induced enhancement of prefrontal activation and the strength of preserved structural connectivity between the frontal and striatal regions. In conclusion, the behavioural effect of citalopram on response inhibition depends on individual differences in prefrontal cortical activation and frontostriatal connectivity. The correlation between disease severity and the effect of citalopram on response inhibition may be due to the progressive loss of forebrain serotonergic projections. These results contribute to a broader understanding of the critical roles of serotonin in regulating cognitive and behavioural control, as well as new strategies for patient stratification in clinical trials of serotonergic treatments in Parkinson's disease.

KW - Aged

KW - Brain

KW - Citalopram

KW - Cross-Over Studies

KW - Diffusion Tensor Imaging

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Impulsive Behavior

KW - Male

KW - Middle Aged

KW - Parkinson Disease

KW - Reaction Time

KW - Serotonin Uptake Inhibitors

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1093/brain/awu032

DO - 10.1093/brain/awu032

M3 - Article

C2 - 24578545

VL - 137

SP - 1145

EP - 1155

JO - Brain

JF - Brain

SN - 1460-2156

IS - Pt 4

ER -